 <h1>Tafenoquine Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to tafenoquine: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, tafenoquine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking tafenoquine:</p><p>
<i>More common</i>
</p><ul>
<li>Bluish-colored lips, fingernails, or palms</li>
<li>dark urine</li>
<li>difficulty breathing</li>
<li>dizziness or lightheadedness</li>
<li>fever</li>
<li>headache</li>
<li>pale skin</li>
<li>rapid heartbeat</li>
<li>sore throat</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Abnormal dreams</li>
<li>anxiety</li>
<li>discouragement</li>
<li>feeling sad or empty</li>
<li>hives or welts, itching, skin rash</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>loss of interest or pleasure</li>
<li>redness of the skin</li>
<li>sleepiness or unusual drowsiness</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Agitation</li>
<li>back, leg, or stomach pains</li>
<li>black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>chills</li>
<li>clay-colored stools</li>
<li>diarrhea</li>
<li>fainting</li>
<li>fast heartbeat</li>
<li>general body swelling</li>
<li>hoarseness</li>
<li>increased sensitivity to pain</li>
<li>increased sensitivity to touch</li>
<li>irritation</li>
<li>joint pain, stiffness, or swelling</li>
<li>nausea</li>
<li>nosebleed</li>
<li>pinpoint red spots on the skin</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>tightness in the chest</li>
<li>tremor</li>
<li>trouble with swallowing</li>
<li>troubled breathing with exertion</li>
<li>unpleasant breath odor</li>
<li>vomiting</li>
<li>vomiting of blood</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of tafenoquine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision or any other change in vision</li>
<li>eye redness, irritation, or pain</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Motion sickness</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Change in color vision</li>
<li>decreased vision</li>
<li>difficulty seeing at night</li>
<li>increased sense of hearing</li>
<li>increased sensitivity of the eyes to sunlight</li>
<li>loss of memory</li>
<li>night blindness</li>
<li>poor coordination</li>
<li>problems with memory</li>
<li>seeing floating dark spots or material before the eyes</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tafenoquine: oral tablet</i></p><h3>General</h3><p>The recommended regimen for the prophylaxis of malaria was evaluated in 5 clinical trials.  The duration of drug exposure in these 5 trials averaged 21 weeks (range: 10 to 29 weeks).  Of the 5 trials, 3 were conducted in healthy semi-immune volunteers in Ghana or Kenya, 1 was in healthy soldiers in East Timor (Timor Leste), and 1 was in healthy volunteers in the US and UK.</p>
<p></p>
<p>In clinical trials in patients with Plasmodium vivax malaria, a single dose of this drug was used with chloroquine.<sup>[Ref]</sup></p><h3>Ocular</h3><p>In the trials that included ophthalmic evaluations, vortex keratopathy was reported in 21% to 93% of subjects receiving this drug; the keratopathy did not cause any apparent functional visual changes and resolved within 1 year after stopping the drug in all patients.</p>
<p></p>
<p>For the prophylaxis of malaria: Keratopathy (5 reports) and retinal disorders (2 reports) were reported as serious ocular adverse reactions in trials that included ophthalmic evaluations.<sup>[Ref]</sup></p><p>For the prophylaxis of malaria:</p>
<p>-Very common (10% or more): Vortex keratopathy (up to 93%)</p>
<p>-Frequency not reported: Retinal abnormalities, retinal disorders, keratopathy, night blindness, photophobia, blurred vision, reduced visual acuity, visual impairment, vitreous floaters</p>
<p></p>
<p>For the radical cure of P vivax malaria:</p>
<p>-Uncommon (0.1% to 1%): Vortex keratopathy, photophobia<sup>[Ref]</sup></p><h3>Nervous system</h3><p>For the prophylaxis of malaria:</p>
<p>-Very common (10% or more): Headache (included headache, sinus headache, migraine, tension headache; up to 32%)</p>
<p>-Common (1% to 10%): Dizziness (included dizziness, postural dizziness), motion sickness (included motion sickness, vertigo, positional vertigo)</p>
<p>-Frequency not reported: Hyperacusis, Meniere's disease, amnesia, abnormal coordination, hyperesthesia, hypoesthesia, somnolence, syncope, tremor, visual field defect</p>
<p></p>
<p>For the radical cure of P vivax malaria:</p>
<p>-Common (1% to 10%): Headache, dizziness</p>
<p>-Uncommon (0.1% to 1%): Somnolence<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>For the prophylaxis of malaria:</p>
<p>-Very common (10% or more): Diarrhea (up to 18%)</p>
<p>-Common (1% to 10%): Nausea, vomiting</p>
<p></p>
<p>For the radical cure of P vivax malaria:</p>
<p>-Common (1% to 10%): Nausea, vomiting<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>For the prophylaxis of malaria:</p>
<p>-Very common (10% or more): Back pain (14%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p>For the prophylaxis of malaria:</p>
<p>-Very common (10% or more): Asymptomatic methemoglobin elevations (13%)</p>
<p>-Common (1% to 10%): Decreased hemoglobin</p>
<p>-Frequency not reported: Hemolytic anemia, anemia, thrombocytopenia</p>
<p></p>
<p>For the radical cure of P vivax malaria:</p>
<p>-Common (1% to 10%): Decreased hemoglobin levels, elevated methemoglobin</p>
<p>-Frequency not reported: Asymptomatic methemoglobin elevations<sup>[Ref]</sup></p><p>For the prophylaxis of malaria: Decreased hemoglobin (at least 3 g/dL) was reported in 2.3% of subjects.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>For the radical cure of P vivax malaria: Cases of depression and psychosis (2 each) have been reported primarily in patients with history of psychiatric disorders after receiving single doses that were higher than the approved 300 mg dose (350 to 600 mg).<sup>[Ref]</sup></p><p>For the prophylaxis of malaria:</p>
<p>-Common (1% to 10%): Any sleep symptom (included abnormal dreams, insomnia, nightmares, sleep disorder, somnambulism), insomnia, abnormal dreams (included abnormal dreams, nightmares), depression/depressed mood, anxiety (included anxiety disorder, panic attack, stress)</p>
<p>-Frequency not reported: Agitation, neurosis</p>
<p></p>
<p>For the radical cure of P vivax malaria:</p>
<p>-Common (1% to 10%): Insomnia</p>
<p>-Uncommon (0.1% to 1%): Anxiety</p>
<p>-Rare (less than 0.1%): Abnormal dreams</p>
<p>-Frequency not reported: Depression, psychosis<sup>[Ref]</sup></p><h3>Renal</h3><p>For the prophylaxis of malaria:</p>
<p>-Frequency not reported: Increased blood creatinine, decreased glomerular filtration rate</p>
<p></p>
<p>For the radical cure of P vivax malaria:</p>
<p>-Common (1% to 10%): Increased blood creatinine<sup>[Ref]</sup></p><h3>Hepatic</h3><p>For the prophylaxis of malaria:</p>
<p>-Common (1% to 10%): Increased/abnormal ALT</p>
<p>-Frequency not reported: Hyperbilirubinemia, cholestatic jaundice, increased blood bilirubin</p>
<p></p>
<p>For the radical cure of P vivax malaria:</p>
<p>-Uncommon (0.1% to 1%): Increased ALT<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>For the prophylaxis of malaria:</p>
<p>-Frequency not reported: Hypersensitivity</p>
<p></p>
<p>For the radical cure of P vivax malaria:</p>
<p>-Rare (less than 0.1%): Hypersensitivity reactions (e.g., angioedema, urticaria)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>For the prophylaxis of malaria:</p>
<p>-Frequency not reported: Urticaria<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Krintafel (tafenoquine)." GlaxoSmithKline, Research Triangle Park, NC. </p><p id="ref_2">2. "Product Information. Arakoda (tafenoquine)." 60 Degrees Pharmaceuticals LLC, Washington, AC. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What is the difference between Arakoda and Krintafel?</li>
<li>How do you take Arakoda for the prevention of malaria?</li>
<li>How do you take Krintafel?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about tafenoquine</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: antimalarial quinolines</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Tafenoquine &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Krintafel, Arakoda</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Malaria</li>
<li>Malaria Prevention</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tafenoquine: oral tablet</i></p><h3>General</h3><p>The recommended regimen for the prophylaxis of malaria was evaluated in 5 clinical trials.  The duration of drug exposure in these 5 trials averaged 21 weeks (range: 10 to 29 weeks).  Of the 5 trials, 3 were conducted in healthy semi-immune volunteers in Ghana or Kenya, 1 was in healthy soldiers in East Timor (Timor Leste), and 1 was in healthy volunteers in the US and UK.</p><p></p><p>In clinical trials in patients with Plasmodium vivax malaria, a single dose of this drug was used with chloroquine.<sup>[Ref]</sup></p><h3>Ocular</h3><p>In the trials that included ophthalmic evaluations, vortex keratopathy was reported in 21% to 93% of subjects receiving this drug; the keratopathy did not cause any apparent functional visual changes and resolved within 1 year after stopping the drug in all patients.</p><p></p><p>For the prophylaxis of malaria: Keratopathy (5 reports) and retinal disorders (2 reports) were reported as serious ocular adverse reactions in trials that included ophthalmic evaluations.<sup>[Ref]</sup></p><p>For the prophylaxis of malaria:</p><p>-Very common (10% or more): Vortex keratopathy (up to 93%)</p><p>-Frequency not reported: Retinal abnormalities, retinal disorders, keratopathy, night blindness, photophobia, blurred vision, reduced visual acuity, visual impairment, vitreous floaters</p><p></p><p>For the radical cure of P vivax malaria:</p><p>-Uncommon (0.1% to 1%): Vortex keratopathy, photophobia<sup>[Ref]</sup></p><h3>Nervous system</h3><p>For the prophylaxis of malaria:</p><p>-Very common (10% or more): Headache (included headache, sinus headache, migraine, tension headache; up to 32%)</p><p>-Common (1% to 10%): Dizziness (included dizziness, postural dizziness), motion sickness (included motion sickness, vertigo, positional vertigo)</p><p>-Frequency not reported: Hyperacusis, Meniere's disease, amnesia, abnormal coordination, hyperesthesia, hypoesthesia, somnolence, syncope, tremor, visual field defect</p><p></p><p>For the radical cure of P vivax malaria:</p><p>-Common (1% to 10%): Headache, dizziness</p><p>-Uncommon (0.1% to 1%): Somnolence<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>For the prophylaxis of malaria:</p><p>-Very common (10% or more): Diarrhea (up to 18%)</p><p>-Common (1% to 10%): Nausea, vomiting</p><p></p><p>For the radical cure of P vivax malaria:</p><p>-Common (1% to 10%): Nausea, vomiting<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>For the prophylaxis of malaria:</p><p>-Very common (10% or more): Back pain (14%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p>For the prophylaxis of malaria:</p><p>-Very common (10% or more): Asymptomatic methemoglobin elevations (13%)</p><p>-Common (1% to 10%): Decreased hemoglobin</p><p>-Frequency not reported: Hemolytic anemia, anemia, thrombocytopenia</p><p></p><p>For the radical cure of P vivax malaria:</p><p>-Common (1% to 10%): Decreased hemoglobin levels, elevated methemoglobin</p><p>-Frequency not reported: Asymptomatic methemoglobin elevations<sup>[Ref]</sup></p><p>For the prophylaxis of malaria: Decreased hemoglobin (at least 3 g/dL) was reported in 2.3% of subjects.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>For the radical cure of P vivax malaria: Cases of depression and psychosis (2 each) have been reported primarily in patients with history of psychiatric disorders after receiving single doses that were higher than the approved 300 mg dose (350 to 600 mg).<sup>[Ref]</sup></p><p>For the prophylaxis of malaria:</p><p>-Common (1% to 10%): Any sleep symptom (included abnormal dreams, insomnia, nightmares, sleep disorder, somnambulism), insomnia, abnormal dreams (included abnormal dreams, nightmares), depression/depressed mood, anxiety (included anxiety disorder, panic attack, stress)</p><p>-Frequency not reported: Agitation, neurosis</p><p></p><p>For the radical cure of P vivax malaria:</p><p>-Common (1% to 10%): Insomnia</p><p>-Uncommon (0.1% to 1%): Anxiety</p><p>-Rare (less than 0.1%): Abnormal dreams</p><p>-Frequency not reported: Depression, psychosis<sup>[Ref]</sup></p><h3>Renal</h3><p>For the prophylaxis of malaria:</p><p>-Frequency not reported: Increased blood creatinine, decreased glomerular filtration rate</p><p></p><p>For the radical cure of P vivax malaria:</p><p>-Common (1% to 10%): Increased blood creatinine<sup>[Ref]</sup></p><h3>Hepatic</h3><p>For the prophylaxis of malaria:</p><p>-Common (1% to 10%): Increased/abnormal ALT</p><p>-Frequency not reported: Hyperbilirubinemia, cholestatic jaundice, increased blood bilirubin</p><p></p><p>For the radical cure of P vivax malaria:</p><p>-Uncommon (0.1% to 1%): Increased ALT<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>For the prophylaxis of malaria:</p><p>-Frequency not reported: Hypersensitivity</p><p></p><p>For the radical cure of P vivax malaria:</p><p>-Rare (less than 0.1%): Hypersensitivity reactions (e.g., angioedema, urticaria)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>For the prophylaxis of malaria:</p><p>-Frequency not reported: Urticaria<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Krintafel (tafenoquine)." GlaxoSmithKline, Research Triangle Park, NC. </p><p id="ref_2">2. "Product Information. Arakoda (tafenoquine)." 60 Degrees Pharmaceuticals LLC, Washington, AC. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is the difference between Arakoda and Krintafel?</li>
<li>How do you take Arakoda for the prevention of malaria?</li>
<li>How do you take Krintafel?</li>
</ul><h2>More about tafenoquine</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: antimalarial quinolines</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Tafenoquine &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Malaria</li>
<li>Malaria Prevention</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>